Co-transduction-aware digital twinning of dual-AAV prime editing for genetically stratified CNS therapy
Abstract Dual-AAV prime editing could deliver precise gene correction to the central nervous system, but its therapeutic yield depends on a chain of events co-delivery of both vectors to the same cell, editor reconstitution, editing, and rescue that is usually measured separately in different systems. This study presents DUAL-AAV PRIME-DT, an evidence-constrained digital twin that treats AAV-A/AAV-B co-transduction as an explicit cell-level state and propagates it through the whole therapeutic chain. In a synthetic cohort of 10,000 virtual patients with LRRK2-associated Parkinson disease, mean therapeutic coverage is 1.24% (patient-level 5th\95th percentile, 0.12–3.93%), with joint delivery and editing causing the largest losses. Perfect co-transduction raises mean coverage by 74%, whereas assuming independent vectors changes it by only − 5%. Stress tests, sensitivity analysis, and value-of-information analysis identify delivery, reconstitution, and editing as principal levers and show that a terminal phenotype cannot reveal which step failed. All outputs are synthetic and imply no clinical efficacy; the framework specifies the matched same-cell measurements required to replace synthetic priors and to test its predictions.
Authors
- Faizan Ahmad (ORCID: https://orcid.org/0000-0002-7768-9411)
Institutions
- Jamia Hamdard (IN)
Publication Details
- Journal
- Research Square
- Published
- 2026-11-17
- DOI
- https://doi.org/10.21203/rs.3.rs-11747124/v1
- Primary Topic
- Virus-based gene therapy research
- Type
- preprint